title: [Influence of antiangiogenetic therapy on retinal thickness values in age-related macular degeneration].
abstract: BACKGROUND
  This study evaluated the impact of antiangiogenetic therapy on differences in central retinal thickness (CRT) as measured with two optical coherence tomography (OCT) systems from the same manufacturer.
  
  
  METHODS
  Data were obtained from a group of 20 patients with neovascular age-related macular degeneration before and after intravitreal treatment with ranibizumab. Imaging was performed using the Stratus and the high-definition (HD) Cirrus OCT systems.
  
  
  RESULTS
  The mean CRT was revealed to be significantly lower as measured by OCT compared with HD-OCT before and after treatment (p<0.002). CRT differences varied more strongly before treatment than after treatment. A higher standard deviation was noted before treatment. The difference in the mean deviation of CRT measurements before and following antiangiogenetic therapy was highly significant.
  
  
  CONCLUSIONS
  This study showed that differences in CRT measurements between different OCT systems were subject not only to technical differences but also to treatment effects of current antiangiogenetic strategies. These effects should be recognized because clinical studies increasingly define OCT parameters as primary or secondary outcome measures.
authors.affiliation: Universitätsklinik für Augenheilkunde und Optometrie, Währinger Gürtel 18-20, 1090, Wien, Osterreich.
authors.forename: I
authors.initials: I
authors.lastname: Golbaz
authors.forename: C
authors.initials: C
authors.lastname: Ahlers
authors.forename: C
authors.initials: C
authors.lastname: Schütze
authors.forename: G
authors.initials: G
authors.lastname: Stock
authors.forename: G
authors.initials: G
authors.lastname: Mylonas
authors.forename: C
authors.initials: C
authors.lastname: Prünte
authors.forename: U
authors.initials: U
authors.lastname: Schmidt-Erfurth
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects* / Q000473:pathology*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab